paediatrics Brussels 17

Treatment of Posterior Fossa Ependymoma Subgroups

A

B

PFS

OS

1.00

1.00

0.75

0.75

GENE Cohort

0.50

0.50

0.25

0.25

PFS (probability) GTR STR

GTR STR

OS (probability)

P < .001

P = .02

Time Since Diagnosis (years) 0 1 2 3 4 5 6 7 8 9 10

0 1 2 3 4 5 6 7 8 9 10 Time Since Diagnosis (years)

No. at risk

GTR STR No. at risk

176148123101 79 67 54 48 39 29 22 87 58 50 38 34 22 17 13 11 9 7 STR GTR

175128 89 70 54 48 40 34 25 18 15 87 50 36 23 16 13 10 8 7 6 4

C

D

1.00

1.00

0.75

0.75

St Jude’s Cohort

0.50

0.50

0.25

0.25

GTR STR

GTR STR

OS (probability)

P = .003

PFS (probability)

P = .007

0 1 2 3 4 5 6 7 8 9 10 Time Since Diagnosis (years)

0 1 2 3 4 5 6 7 8 9 10 Time Since Diagnosis (years)

Fig 2. (A, C, E, and G) Progression-free survival (PFS) and (B, D, F, and H) overall survival (OS) of EPN_PFA strati fi ed by extent of resection across all four cohorts. CERN, Collaborative Ependymoma Research Net- work; GENE, Global Ependymoma Network of Excellence; GTR, gross total resection; STR, subtotal resection ( . 5 mm residual disease). P values determined using log- rank test.

GTR STR No. at risk

GTR STR No. at risk

84 84 80 75 73 71 65 55 51 44 39 20 19 19 15 12 11 10 10 9 6 4

84 82 70 59 58 56 51 43 40 36 33 20 17 13 11 10 9 7 7 6 3 2

E

F

1.00

1.00

0.75

0.75

CERN Cohort

0.50

0.50

0.25

0.25

OS (probability) GTR STR

GTR STR

PFS (probability)

P = .06

P = .2

0 1 2 3 4 5 6 7 8 9 10 Time Since Diagnosis (years)

0 1 2 3 4 5 6 7 8 9 10 Time Since Diagnosis (years)

GTR STR No. at risk

GTR STR No. at risk

49 48 43 39 33 31 24 19 13 9 7 37 35 30 27 24 21 17 12 9 7 6

49 48 43 39 33 31 24 19 13 9 7 37 35 30 27 24 21 17 12 9 7 6

G

H

1.00

1.00

0.75

0.75

Burdenko Cohort

0.50

0.50

0.25

0.25

GTR STR

GTR STR

OS (probability)

P = .01

PFS (probability)

P < .001

0 1 2 3 4 5 6 7 8 9 10 Time Since Diagnosis (years)

0 1 2 3 4 5 6 7 8 9 10 Time Since Diagnosis (years)

GTR STR No. at risk

GTR STR No. at risk

114105 88 71 59 49 40 35 19 16 11 97 88 73 54 41 29 20 11 8 7 5

114 92 68 51 42 32 26 22 12 10 7 98 67 46 29 17 13 7 5 5 5 4

© 2016 by American Society of Clinical Oncology 5

www.jco.org

from 139.18.224.1 Information downloaded from jco.ascopubs.org and provided by at UNIVERSITAETSKLINIKUM LEIPZIG on June 20, 2016 Copyright © 2016 American S ciety of Clinical Oncology. All rights reserved.